Cosmo Pharmaceuticals N.V. (“Cosmo”) today announced positive 12-month Phase III results for Clascoterone 5% topical solution in men with mild-to-moderate androgenetic alopecia (AGA), reinforcing the product’s potential to redefine treatment in one of the largest and most underserved categories in dermatology. The data confirm three critical attributes physicians and patients have been waiting for: long-term safety, continued efficacy with ongoing use, and a novel mechanism designed to target the underlying biology of hair loss.